Menu
Back to Journals » OncoTargets and Therapy » Volume 6
Update on oncolytic viral therapy – targeting angiogenesis
Authors Tysome JR, Lemoine NR, Wang Y
Received 19 April 2013
Accepted for publication 1 June 2013
Published 31 July 2013 Volume 2013:6 Pages 1031—1040
DOI https://doi.org/10.2147/OTT.S46974
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
James R Tysome,1–3 Nick R Lemoine,1,3 Yaohe Wang1,3
1Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; 2Department of Otolaryngology, Cambridge University Hospitals, Cambridge, United Kingdom; 3Sino-British Research Center for Molecular Oncology, Zhengzhou University, Zhengzhou, People's Republic of China
Abstract: Oncolytic viruses (OVs) have the ability to selectively replicate in and lyse cancer cells. Angiogenesis is an essential requirement for tumor growth. Like OVs, the therapeutic effect of many angiogenesis inhibitors has been limited, leading to the development of more effective approaches to combine antiangiogenic therapy with OVs. Angiogenesis can be targeted either directly by OV infection of vascular endothelial cells, or by arming OVs with antiangiogenic transgenes, which are subsequently expressed locally in the tumor microenvironment. In this review, we describe the development and targeting of OVs, the role of angiogenesis in cancer, and the progress made in arming viruses with antiangiogenic transgenes. Future developments required to optimize this approach are addressed.
Keywords: oncolytic virotherapy, cancer
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.